Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01539239 |
Recruitment Status :
Completed
First Posted : February 27, 2012
Results First Posted : September 6, 2019
Last Update Posted : March 12, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Primary Open Angle Glaucoma | Device: Hydrus Aqueous Implant Procedure: Cataract surgery | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1143 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial |
Study Start Date : | January 2012 |
Actual Primary Completion Date : | June 2017 |
Actual Study Completion Date : | June 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Hydrus Aqueous Implant (Treatment)
Cataract surgery plus Hydrus Aqueous Implant
|
Device: Hydrus Aqueous Implant
The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL. |
Active Comparator: Cataract Surgery (Control)
Cataract surgery only
|
Procedure: Cataract surgery
A monofocal intraocular lens (IOL) placed during the cataract surgery. |
- Reduction in Mean Diurnal IOP From Baseline at 24 Months Following Medication Washout. [ Time Frame: Baseline and 24 months ]Percentage of eyes in which diurnal IOP was reduced by greater than or equal to 20% at 24 months postoperative compared to baseline after washout of topical glaucoma medications.
- Mean Diurnal Washed Out IOP Change From Baseline at 24 Months Compared Between Treatment and Control Groups. [ Time Frame: Baseline and 24 months ]Mean diurnal IOP change from baseline at 24 months between both groups after washout of topical glaucoma medications.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- An operable age-related cataract
- A diagnosis of POAG treated with 1 to 4 hypotensive medications
- Medicated IOP ≤ 31 mmHg
- Diurnal IOP ≥ 22 mmHg and ≤ 34 mmHg
Exclusion Criteria:
- Congenital or developmental glaucoma
- Previous argon laser trabeculoplasty
- Ab-interno or ab-externo device implanted in or through Schlemm's Canal
- Use of oral hypotensive medication for glaucoma for treatment of fellow eye

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01539239
United States, Arizona | |
Phoenix, Arizona, United States | |
Tucson, Arizona, United States | |
United States, Arkansas | |
Fayetteville, Arkansas, United States | |
United States, California | |
La Jolla, California, United States | |
Orange, California, United States | |
Sacramento, California, United States | |
United States, Colorado | |
Fort Collins, Colorado, United States | |
Parker, Colorado, United States | |
United States, Florida | |
Bradenton, Florida, United States | |
Fort Myers, Florida, United States | |
Ocala, Florida, United States | |
United States, Iowa | |
Sioux City, Iowa, United States | |
United States, Kansas | |
Garden City, Kansas, United States | |
United States, Kentucky | |
Louisville, Kentucky, United States | |
United States, Massachusetts | |
Sandwich, Massachusetts, United States | |
United States, Minnesota | |
Bloomington, Minnesota, United States | |
United States, Missouri | |
Chesterfield, Missouri, United States | |
United States, North Carolina | |
Wilmington, North Carolina, United States | |
United States, Ohio | |
Cleveland, Ohio, United States | |
Mason, Ohio, United States | |
United States, Tennessee | |
Maryville, Tennessee, United States | |
United States, Texas | |
Austin, Texas, United States | |
Dallas, Texas, United States | |
Fort Worth, Texas, United States | |
United States, Utah | |
Salt Lake City, Utah, United States | |
United States, Wisconsin | |
Racine, Wisconsin, United States | |
Canada, Alberta | |
Edmonton, Alberta, Canada | |
Canada, Quebec | |
Boisbriand, Quebec, Canada | |
Germany | |
Mainz, Germany | |
Italy | |
Parma, Italy | |
Mexico | |
Tijuana, Mexico | |
Philippines | |
Manila, Philippines | |
Poland | |
Warsaw, Poland | |
Spain | |
Madrid, Spain | |
Zaragoza, Spain | |
United Kingdom | |
London, United Kingdom | |
Manchester, United Kingdom | |
Norwich, United Kingdom |
Principal Investigator: | Alan Crandall, MD | The Eye Institute of Utah |
Documents provided by Ivantis, Inc.:
Responsible Party: | Ivantis, Inc. |
ClinicalTrials.gov Identifier: | NCT01539239 |
Other Study ID Numbers: |
CP-11-001 |
First Posted: | February 27, 2012 Key Record Dates |
Results First Posted: | September 6, 2019 |
Last Update Posted: | March 12, 2021 |
Last Verified: | February 2021 |
Glaucoma POAG Cataract |
Glaucoma Cataract Glaucoma, Open-Angle |
Ocular Hypertension Eye Diseases Lens Diseases |